Genmab — September 2018
-
-
@Sukkeralf. Jeg er bare overrasket over man ikke kan få en bedre aftale selvom det er den første. Købte JnJ sig ikke til 20 skud i bøssen i sin tid. Med lidt tillid til egen platform, havde jeg håbet på højere royalties. Never mind. Dit link kan jeg i øvrigt ikke få til at virke.
-
“Our cutting edge science and passion for innovation are at Genmab’s core. We are very excited to provide an update on the robust progress with our world-class innovative pipeline, as well as introducing HexElect, our novel next generation antibody therapeutics platform. This technology has been inspired by Genmab’s HexaBody technology and unlocks potency by making the action of two HexaBody molecules dependent on binding to two different targets on the same cell. ..
-
for duobody så vi at patentansøgningen røg afsted i 2007 og den optrådte første gang offentligt på en GEN-update I 2011. I går så vi første spæde tegn på klinisk effekt (nice find, by the way!)
-
Så der er vist ingen grund til at få knuder i trusserne endnu, fordi der bliver annonceret en ny teknologiplatform
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind